Viatris celebrates 25 years of journey to improve heart health in Vietnam

According to the World Health Organization (WHO) report in 2023, cardiovascular disease is the leading cause of death globally, with more than 75% of deaths occurring in low- and middle-income countries, including Vietnam. Statistics show that about 30% of Vietnamese adults have dyslipidemia - one of the main risk factors for atherosclerotic cardiovascular disease, causing serious events such as myocardial infarction and stroke.

Scientific seminar “Atorvastatin: 25-year journey for Cardiovascular Health – Inheriting the present, firmly stepping into the future”

In this context, statins, cholesterol synthesis inhibitors, have been shown to significantly reduce the risk of myocardial infarction, stroke, and cardiovascular death in a wide range of patients with risk factors such as dyslipidemia, type 2 diabetes, and patients with established atherosclerotic cardiovascular disease such as chronic coronary artery disease, acute coronary syndrome, and stroke. Therefore, statins, especially high-potency statins, have become the cornerstone of strategies for controlling dyslipidemia and cardiovascular outcomes worldwide .

Affirming the revolutionary importance of this group of drugs, Associate Professor, Dr. Chau Ngoc Hoa, Vice President of the Vietnam Cardiology Association, emphasized: “ In the history of medicine, if Penicillin opened a revolution to repel infectious diseases, then statin is the second revolution, contributing to repelling cardiovascular diseases caused by atherosclerosis and saving millions of lives since being put into clinical use in the late 1980s .”

Among statins, Atorvastatin is a highly active statin that has accompanied the medical team for the past 25 years. To celebrate this memorable milestone, Viatris organized a series of scientific events to honor the journey of accompanying patients, and reaffirmed its commitment to continue working closely with medical professionals in the goal of reducing the burden of cardiovascular disease and improving public health in Vietnam.

The highlight of the series of activities is the in-depth scientific conference with the theme “Atorvastatin: 25-year journey for Cardiovascular Health – Inheriting the present, firmly stepping into the future”, jointly organized with the Vietnam Cardiovascular Association. The event attracted more than 400 leading medical experts in the fields of cardiovascular, endocrinology, stroke and nephrology in the Southern region. Here, the experts reviewed the role of Atorvastatin in the journey of protecting patients from primary to secondary.

Speaking at the conference, Prof. Dr. Truong Quang Binh, Chairman of the Vietnam Atherosclerosis Association, said: " With much clinical evidence, Atorvastatin has proven effective in preventing cardiovascular events in many different patient groups and always accompanies the work of protecting cardiovascular health for the community ."

Not only focusing on expertise, Viatris also continues to spread positive messages to the community. Specifically, the company organized the seminar "Don't miss the precious moment" for all employees on World Heart Day, and sponsored the "25 years of steady steps - For a century of raising the level of protection of Vietnamese Heart" run organized by the Vietnam Community Project Board. These activities aim to promote the importance of prevention and health education for people, thereby contributing to building a sustainable preventive cardiovascular care ecosystem.

“ Viaticris is proud to be one of the pioneers in bringing high-quality statins to Vietnamese patients over the past 25 years. We are committed to continuing to accompany healthcare professionals in raising awareness of cardiovascular health care in the community, for a healthier Vietnam ” - Ms. Radhika Bhalla, General Director of Viatris Vietnam and Asian Union Markets, shared more about the company's development goals and orientation.

With extensive scientific expertise, a diverse drug portfolio and a global supply chain, Viatris is confident that it will continue to expand access to healthcare for patients, contributing to protecting cardiovascular health in particular and controlling non-communicable diseases in general in Vietnam.

LAM HA

Source: https://www.sggp.org.vn/viatris-ky-niem-25-nam-hanh-trinh-nang-cao-suc-khoe-tim-mach-tai-viet-nam-post820804.html